Related Experiment Videos
Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial
1Department of Medicine, Yale University School of Medicine, and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation, Conn, USA.
Insights
Beta-blocker therapy after acute myocardial infarction (AMI) reduces mortality in elderly patients, including those undergoing coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA). Routine consideration of beta-blockers is recommended for revascularized AMI patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Randomized trials show beta-blockers reduce mortality post-acute myocardial infarction (AMI).
- Many trials excluded patients undergoing coronary revascularization.
- Clinical guidelines recommend beta-blockers for revascularized AMI patients.
Purpose of the Study:
- To compare beta-blocker initiation at discharge in elderly AMI patients who underwent coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) versus those who did not.
- To examine the association between beta-blocker therapy and 1-year mortality in revascularized versus non-revascularized AMI patients.
Main Methods:
- Utilized data from the Cooperative Cardiovascular Project.
- Included patients aged 65 years or older hospitalized for AMI.
- Compared beta-blocker initiation and 1-year mortality between revascularized (CABG/PTCA) and non-revascularized groups, adjusting for demographic and clinical factors.
Main Results:
- 84,457 patients were analyzed after excluding those with beta-blocker contraindications.
- Revascularized patients (CABG/PTCA) were less likely to initiate beta-blockers post-discharge compared to non-revascularized patients.
- Beta-blockers were associated with significantly lower 1-year mortality in both revascularized (CABG/PTCA) and non-revascularized groups.
Conclusions:
- Beta-blocker therapy demonstrates similar effectiveness in reducing 1-year mortality for elderly patients after AMI, regardless of whether they underwent CABG or PTCA.
- Findings support the routine consideration of beta-blocker therapy for patients undergoing revascularization after AMI.
Background:
Although randomized clinical trials have demonstrated that beta-blocker therapy is effective in reducing mortality after acute myocardial infarction (AMI), many of these studies excluded patients who undergo coronary revascularization. However, the clinical practice guidelines established by the American College of Cardiology and the American Heart Association recommend that beta-blocker therapy be considered for patients who underwent successful revascularization after AMI.
Methods:
Using data from the Cooperative Cardiovascular Project, we compared the initiation of beta-blocker therapy at discharge in patients aged 65 years or older who underwent coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) during their hospitalization for AMI with that of patients who did not undergo revascularization. We then examined whether beta-blocker therapy was associated with lower 1-year mortality between revascularized and nonrevascularized groups.
Results:
After excluding patients with contraindications to beta-blocker therapy, 84 457 patients remained in the study sample. Of these, 8482 patients underwent CABG, and 13 997 patients underwent PTCA. After adjusting for demographic and clinical factors, we found that these patients were less likely to initiate beta-blocker therapy after CABG (odds ratio [OR], 0.44; 95% confidence interval [CI], 0.41-0.47) or PTCA (OR, 0.89; 95% CI, 0.85-0.93) relative to the nonrevascularized group. After adjusting for potential confounders, beta-blockers were significantly associated with lower 1-year mortality in patients who underwent CABG (hazard ratio [HR], 0.70; 95% CI, 0.55-0.89) or PTCA (HR, 0.86; 95% CI, 0.74-1.00), similar to that of the non-revascularized group (HR, 0.83; 95% CI, 0.80-0.87).
Conclusions:
Therapy after AMI with beta-blockers appears to be as effective in reducing 1-year mortality for elderly patients who have undergone CABG or PTCA as for a nonrevascularized group. Our findings suggest that routine use of beta-blockers should be considered for patients who undergo revascularization after AMI.